Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M183,667Revenue (TTM) $M41,260Net Margin (%)3.3Altman Z-Score3.6
Enterprise Value $M199,648EPS (TTM) $0.5Operating Margin %14.8Piotroski F-Score7
P/E(ttm)138Beneish M-Score-2.8Pre-tax Margin (%)13.4Higher ROA y-yN
Price/Book5.710-y EBITDA Growth Rate %-0.2Quick Ratio1.0Cash flow > EarningsY
Price/Sales4.65-y EBITDA Growth Rate %-5.9Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow36.0y-y EBITDA Growth Rate %-2.2ROA % (ttm)1.5Higher Current Ratio y-yN
Dividend Yield %2.8PEG--ROE % (ttm)3.8Less Shares Outstanding y-yY
Payout Ratio %382Shares Outstanding M2,660ROIC % (ttm)3.0Gross Margin Increase y-yY

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

MRK is held by these investors:



MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Chattopadhyay SanatExe V-P & Pres. MMD 2018-08-03Sell29,208$65.25.92view
Karachun Rita ASr. VP Fince-Global Controller 2018-08-02Sell5,000$65.016.23view
FRAZIER KENNETH CChairman, President & CEO 2018-07-31Sell228,091$656.25view
Schechter Adam HEVP & Pres-Global Human Health 2018-06-18Sell134,094$6113.21view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2018-05-15Sell9,972$59.6615.76view
GRADDICK WEIR MIRIAN MExe V-P, HR 2018-04-16Sell24,000$5819.07view
WEEKS WENDELL PDirector 2018-02-09Sell5,000$53.5728.92view
Schechter Adam HEVP & Pres-Global Human Health 2018-01-16Sell101,602$61.6312.06view
Holston Michael JEVP, General Counsel 2018-01-16Sell12,500$61.6312.06view
GRADDICK WEIR MIRIAN MExe V-P, HR 2018-01-16Sell65,000$61.3512.57view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

News about MRK:

Articles On GuruFocus.com
Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patien Aug 17 2018 
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Aug 17 2018 
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Aug 16 2018 
US Market Indexes Close Mostly Lower on Thursday, Tech Stocks Gain Aug 09 2018 
Top 5 Performing Stocks in Most Broadly Held Portfolio Aug 09 2018 
Jeff Auxier Comments on Merck and Co. Aug 08 2018 
Steven Cohen Sees Value in Nightstar Therapeutics Aug 08 2018 
'One Up on Wall Street': A Dozen Investing Fallacies Aug 07 2018 
US Market Indexes Close Higher on Friday Aug 03 2018 
Pfizer Rises on Earnings Beat Jul 31 2018 

More From Our Partners
Merck, Eisai Get FDA Approval for Lenvima Label Expansion Aug 17 2018 - ZACKS
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK